Department of Biochemistry, MMIMSR, Mullana, Ambala, India.
MMIMSR, Mullana, Ambala, India.
Indian Heart J. 2020 May-Jun;72(3):189-191. doi: 10.1016/j.ihj.2020.05.008. Epub 2020 May 27.
The present study aimed to establish a better marker for the assessment of coronary artery disease (CAD).
One hundred patients of CAD (aged 20-60 years) of both sex and patients of hypertension with symptoms of CAD were selected for the study.50 age and sex matched healthy controls were chosen for the present study. Serum total cholesterol, triglycerides and HDL-C were estimated in Simens Dimensions RxL. LDL-C, VLDL-C were calculated by Friedwald Formula while non-HDL-C was calculated by subtracting HDL-C level from total cholesterol level. The comparison of non-HDL-C and friedwald calculated LDL-C was made in terms of independent't' test, serum TG levels (TG ≤ 200 mg/dl and TG > 200 mg/dl) and area under receiver operating characteristic (AUROC) curve.
RESULTS & CONCLUSION: The non-HDL-C levels (mean ± S.D) were higher in both test and control groups to that of the levels of friedwald calculated LDL-C. The area under receiver operating characteristic (AUROC) curve was significantly higher for non-HDL-C than for friedwald calculated LDL-C. The predictive value of non-HDL-C and friedwald calculated LDL-C were also compared in group A (serum TG ≤ 200 mg/dl) and group B (serum TG > 200 mg/dl). Non-HDL-C levels showed a significant difference in both the groups while the results were non-significant to that of friedwald calculated LDL. Thus, non-HDL-C is much specific and sensitive parameter for assessment of CAD risk. Moreover, non-HDL-C levels can also be done in non-fasting state with accuracy, thereby, it is patient friendly parameter. Therefore, the authors strongly suggest the incorporation of non-HDL-C in routine lipid profile panel.
本研究旨在建立一种更好的标志物来评估冠状动脉疾病(CAD)。
本研究选取了 100 例年龄在 20-60 岁之间的 CAD 患者(男女患者)和有 CAD 症状的高血压患者,选择了 50 名年龄和性别匹配的健康对照者。在西门子 Dimensions RxL 上评估血清总胆固醇、甘油三酯和高密度脂蛋白胆固醇。采用 Friedwald 公式计算 LDL-C,VLDL-C 由 Friedwald 公式计算,非高密度脂蛋白胆固醇由总胆固醇水平减去高密度脂蛋白胆固醇水平计算。采用独立't'检验比较非高密度脂蛋白胆固醇和 Friedwald 计算的 LDL-C,比较血清甘油三酯水平(TG≤200mg/dl 和 TG>200mg/dl)和接收者操作特征(ROC)曲线下面积(AUROC)。
两组患者的非高密度脂蛋白胆固醇水平(均值±标准差)均高于 Friedwald 计算的 LDL-C 水平。ROC 曲线下面积(AUROC)非高密度脂蛋白胆固醇明显高于 Friedwald 计算的 LDL-C。还比较了非高密度脂蛋白胆固醇和 Friedwald 计算的 LDL-C 在 A 组(血清 TG≤200mg/dl)和 B 组(血清 TG>200mg/dl)中的预测价值。非高密度脂蛋白胆固醇水平在两组中均有显著差异,而结果与 Friedwald 计算的 LDL 无显著差异。因此,非高密度脂蛋白胆固醇是评估 CAD 风险的特异性和敏感性更高的参数。此外,非高密度脂蛋白胆固醇水平也可以在非禁食状态下准确检测,因此是一种适合患者的参数。因此,作者强烈建议将非高密度脂蛋白胆固醇纳入常规血脂谱检测。